| PFE |
Report |
Q2 2026 revenue |
IN-LINE |
pred ~$14.58B vs. cons $14.48B |
MEDIUM |
| PFE |
Report |
Q2 2026 adjusted diluted EPS |
BEAT |
pred ~$0.70 vs. cons $0.68 |
MEDIUM |
| PFE |
Report |
Q2 2026 Padcev revenue |
BEAT |
pred ~$0.68B vs. cons $0.66B |
MEDIUM |
| PFE |
Guide |
Full-year revenue guidance midpoint |
UNCHANGED |
guide ~$61.0B vs. cons $61.8B (FY2026) |
HIGH |
| PFE |
Guide |
Full-year adjusted diluted EPS guidance midpoint |
UNCHANGED |
guide ~$2.90 vs. cons $2.96 (FY2026) |
HIGH |
| PFE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| PFE |
Return |
5-day cumulative residual |
+0.3% (FADE) |
A modest Q2 EPS beat supports the initial reaction, but unchanged FY2026 guidance at a ~$2.90 EPS midpoint versus $2.96 consensus and ~$61.0B revenue midpoint versus $61.8B consensus limits estimate revisions; the implied second-half revenue requirement remains roughly $32.0B versus Street math near $32.8B. |
MEDIUM |